非瓣膜病心房颤动患者口服新型抗凝药依从性的影响因素分析  

Analysis of Influencing Factors of Compliance of New Oral Anticoagulants in Patients with Non-Valvular Atrial Fibrillation

作　　者：王景安 朱正炎 Wang Jing-an;Zhu Zheng-yan(Department of Cardiology,Beijing Shunyi Hospital,Beijing 101300,China)

机构地区：[1]北京市顺义区医院心内科,北京101300

出　　处：《中国社区医师》2023年第6期7-9,共3页Chinese Community Doctors

摘　　要：目的:分析非瓣膜病心房颤动患者口服新型抗凝药依从性的影响因素。方法:回顾分析2020年4月—2022年4月北京市顺义区医院收治的120例口服新型抗凝药的非瓣膜病心房颤动患者的临床资料。通过Morisky用药依从性量表调查并评估其用药依从性,实施单因素与多因素分析。结果:120例非瓣膜病心房颤动口服新型抗凝药患者中,依从性较好74例,占61.67%;依从性较差46例,占38.33%。影响非瓣膜病心房颤动患者口服新型抗凝药依从性的因素有年龄、合并冠心病、阵发性房颤、心力衰竭≥3级、CHA2DS2-VASc评分≥5分、服用药物≥5种、合并脑卒中、文化程度,差异有统计学意义(P<0.05)。多因素分析结果显示,非瓣膜病心房颤动患者口服新型抗凝药依从性的独立影响因素包括年龄、阵发性房颤、合并冠心病、合并脑卒中、CHA2DS2-VASc评分≥5分,差异有统计学意义(P<0.05)。结论:非瓣膜病心房颤动患者口服新型抗凝药依从性的影响因素较多,应围绕影响因素加强管理。Objective:To analyze the factors affecting the compliance of new oral anticoagulants in patients with non-valvular atrial fibrillation.Methods:A retrospective analysis of the clinical data of 120 patients with non-valvular atrial fibrillation treated with new oral anticoagulants in the Beijing Shunyi Hospital from April 2020 to April 2022 was conducted.The medication compliance was surveyed and assessed using Morisky Medication Adherence Scale,univariate and multivariate analyses were performed.Results:Among 120 patients with non-valvular atrial fibrillation treated with new oral anticoagulants,74 cases had good compliance,accounting for 61.67%;46 cases had poor compliance,accounting for 38.33%.The factors affecting the compliance of new oral anticoagulants in patients with non-valvular atrial fibrillation included age,concurrent coronary heart disease,paroxysmal atrial fibrillation,heart failure≥3 grade,CHA2DS2-VASc score≥5 points,mediated drugs≥5 drugs,concurrent stroke and education level,and the difference was statistically significant(P<0.05).Multivariate analysis results showed that,the independent influencing factors for the compliance of new oral anticoagulants in patients with non-valvular atrial fibrillation included age,paroxysmal atrial fibrillation,concurrent coronary heart disease,concurrent stroke and CHA2DS2-VASc score≥5 points,andand the difference was statistically significant(P<0.05).Conclusion:There are many influencing factors for the compliance of new oral anticoagulants in patients with non-valvular atrial fibrillation,and management should be strengthened targeted the influencing factors.

关 键 词：非瓣膜病心房颤动 新型抗凝药 依从性 

分 类 号：R541.75[医药卫生—心血管疾病]